Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results

Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million
Confirms Adjusted EBITDA within Guidance Range of $120 million to $124 million

RADNOR, Pa., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of fiscal year 2024 based on a preliminary review of fourth quarter results.

Read more at globenewswire.com